Back to Search

MICHAEL ROACH, MD

MD

Thoracic Surgery (Cardiothoracic Vascular Surgery) Physician

NPI: 1487697801IndividualAccepts Medicare

Specialties, Licenses & Credentials

Surgery Physician

Surgery

Code: 208600000X

2013-00469(NC)
Thoracic Surgery (Cardiothoracic Vascular Surgery) PhysicianPrimary

Thoracic Surgery (Cardiothoracic Vascular Surgery)

Code: 208G00000X

2013-00469(NC)

CMS Specialties

PrimaryTHORACIC SURGERY

Additional

CARDIAC SURGERY

Education

EAST TENNESSEE STATE UNIVERSITY QUILLEN COLLEGE OF MEDICINE

Class of 2001

Research & Publications (20)

Predictive models in external beam radiotherapy for clinically localized prostate cancer.
PMID 19544539·Cancer·2009
6-review
Microarray analysis of developing flax hypocotyls identifies novel transcripts correlated with specific stages of phloem fibre differentiation.
PMID 18593690·Ann Bot·2008
8-other
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
PMID 18172188·J Clin Oncol·2008
3-trial
Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both?
PMID 18167004·Strahlenther Onkol·2007
4-observational
Microarray analysis of flax (Linum usitatissimum L.) stems identifies transcripts enriched in fibre-bearing phloem tissues.
PMID 17503083·Mol Genet Genomics·2007
8-other
Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial.
PMID 17498886·Int J Radiat Oncol Biol Phys·2007
3-trial
Goserelin acetate in combination with radiotherapy for prostate cancer.
PMID 17257094·Expert Opin Pharmacother·2007
6-review
Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score?
PMID 17167758·Cancer·2007
8-other
Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials.
PMID 17084158·J Urol·2006
8-other
Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial.
PMID 17011443·Int J Radiat Oncol Biol Phys·2006
2-rct
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.
PMID 16798415·Int J Radiat Oncol Biol Phys·2006
8-other
Radiotherapy plus adjuvant goserelin improves survival in men with poor prognosis prostate cancer.
PMID 16256275·Cancer Treat Rev·2005
8-other
Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study.
PMID 15590164·Int J Radiat Oncol Biol Phys·2004
3-trial
Reducing the toxicity associated with the use of radiotherapy in men with localized prostate cancer.
PMID 15123413·Urol Clin North Am·2004
6-review
Hormonal therapy and radiotherapy for localized prostate cancer: who, where and how long?
PMID 14610408·J Urol·2003
6-review
Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.
PMID 12743142·J Clin Oncol·2003
3-trial
Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostate.
PMID 12670556·Urology·2003
4-observational
Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials.
PMID 12478146·J Urol·2003
8-other
Spectroscopy in prostate cancer: hope or hype?
PMID 11758871·Oncology (Williston Park)·2001
6-review
Proximal ligand control of heme iron coordination structure and reactivity with hydrogen peroxide: investigations of the myoglobin cavity mutant H93G with unnatural oxygen donor proximal ligands.
PMID 11051562·J Inorg Biochem·2000
7-preclinical

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Via practice · 4 locations total

Address
1237 HARDING PL, STE 4300
CHARLOTTE, NC 28204

Locations (4)

Practice Location

1237 HARDING PL, CHARLOTTE, NC
(704) 373-0212

Practice Location

10650 PARK RD, CHARLOTTE, NC
(704) 667-3840

Practice Location

1021 MOREHEAD MEDICAL DR, CHARLOTTE, NC
(980) 442-2000

Practice Location

200 MEDICAL PARK DR, CONCORD, NC
(704) 403-1349

Quick Facts

NPI
1487697801
Entity Type
Individual
Gender
Male
Medicare
Accepted
Specialties
2
Locations
4
Years in Practice
25
Publications
20

Are you this provider?

Claim Your Profile